CAR T-Cell FDA Investigation: Addressing Concerns & Managing CAR T-Cell Referrals for Community Oncologists

To participate in this activity, please:

Log in Sign Up

Chimeric antigen receptor (CAR) T-cell therapies have transformed patient outcomes and treatment approaches for patients with difficult-to-treat hematologic malignancies, leading to improved overall survival compared to traditional salvage treatment options. However, recent reports of rare secondary T-cell malignancies, which led to an FDA investigation and subsequent black box warning for all CAR T-cell therapies, caused confusion among patients and clinicians related to the safety and role of CAR T-cell therapy. Gilles Salles, MD, PhD, provides his insights to address this confusion by clarifying the benefits vs risks of CAR T-cell therapies, with recommendations for patient education, referrals, and treatment integration and individualization.

Please visit our related course, Interprofessional Care of Patients Treated with CAR T-Cell Therapy, by clicking here.

Course Credit:

0.50 AMA PRA Category 1 CreditsTM

Dates:

Opens: 2025-02-27
Closes: 2026-02-27

Target Audience:

This activity is intended for medical hematologists/oncologists, pharmacists, nurse practitioners, physician associates, nurses, and other team members such as hospitalists and emergency medicine clinicians, and staff who manage patients with serious CAR T adverse events of novel therapies (including rare secondary malignancies).

This activity is supported by an independent educational grant from Novartis Pharmaceuticals Corporation.

Accreditation Information

    Presenting Faculty

  • Gilles Salles, MD, PhD headshot

    Gilles Salles, MD, PhD

    Service Chief, Lymphoma Service
    Steven Greenberg Chair
    Memorial Sloan Kettering Cancer Center
    Weill Cornell Medical College
    New York, New York